Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Phase 3 Completed 163 enrolled Anthera Pharmaceuticals

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a clinical trial which will evaluate the efficacy of Liprotamase treatment in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (PI).

Timeline

Start: 2007-05
Primary completion: 2008-06
Completion: 2008-06

Publications

Somaraju URR, Solis-Moya A. Pancreatic enzyme replacement therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2020 Aug 5;8(8):CD008227. doi: 10.1002/14651858.CD008227.pub4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liprotamase	Protein / enzyme biologic	3750 iu	Oral
Subject	Liprotamase	Protein / enzyme biologic	25000 iu	Oral
Subject	Liprotamase	Protein / enzyme biologic	32500 iu	Oral

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Summary

Timeline

Publications

Drugs

Indications